02024nas a2200421 4500000000100000008004100001260001300042653001500055653001000070653001000080653001900090653003000109653001300139653001100152653001100163653002300174653001200197653000900209653001600218653002100234653003900255653001500294653001700309653003000326653003100356653001700387653001600404100001700420700001400437700001500451245009800466856005100564300001000615490000700625050003200632520092400664022001401588 2008 d c2008 Sep 10 aAdolescent 10 aAdult 10 aChild 10 aCohort Studies 10 aDrug Therapy, Combination 10 aEthiopia 10 aFemale 10 aHumans 10 aLeprostatic Agents 10 aleprosy 10 aMale 10 aMiddle Aged 10 aPain Measurement 10 aPeripheral Nervous System Diseases 10 aRecurrence 10 aRisk Factors 10 aSeverity of Illness Index 10 aSurveys and Questionnaires 10 aTime Factors 10 aYoung Adult 1 aSaunderson P 1 aBizuneh E 1 aLeekassa R 00 aNeuropathic pain in people treated for multibacillary leprosy more than ten years previously. uhttps://leprosyreview.org/article/79/3/27-0276 a270-6 0 v79 aInfolep Library - available 3 aOBJECTIVES: To identify patients with typical symptoms of neuropathic pain in a well-defined cohort of multibacillary patients being followed up as part of a relapse study in Ethiopia; to identify risk factors for the development of neuropathic pain.
DESIGN: 96 patients who had completed MDT more than 10 years previously participated in the study, through a questionnaire.
RESULTS: 28 (29%) had symptoms of neuropathic pain and it was reported as severe in 12. Because the past history of these subjects is well documented, a risk factor analysis was carried out. The presence of leprosy-related impairment was the only significant risk factor for neuropathic pain that was identified.
CONCLUSIONS: Neuropathic pain is an important problem in a proportion of people previously treated for leprosy. Further research into the management of the condition is required.
a0305-7518